Translating glutamate: From pathophysiology to treatment

Science Translational Medicine

Volumn 3, Issue 102, 2011, Pages

  Javitt, Daniel C ^a   Schoepp, Darryle ^b   Kalivas, Peter W ^c   Volkow, Nora D ^d   Zarate, Carlos ^e   Merchant, Kalpana ^f   Bear, Mark F ^g   Umbricht, Daniel ^h   Hajos, Mihaly ⁱ   Potter, William Z ^j   Lee, Chi Ming ^k  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ PFIZER INC   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; AZD 6765; BIOLOGICAL MARKER; EGLUMETAD; GLUTAMIC ACID; KETAMINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; POMAGLUMETAD METHIONIL; TALAGLUMETAD; TRAXOPRODIL; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANXIETY DISORDER; AUDITORY RESPONSE; AUTISM; BIPOLAR DEPRESSION; CONFERENCE PAPER; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; MAJOR DEPRESSION; MISMATCH NEGATIVITY; MOLECULAR PATHOLOGY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROIMAGING; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; STEADY STATE; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; MOUSE; NEUROLOGIC DISEASE; ORGANIZATION; PATHOPHYSIOLOGY; REVIEW; TRANSLATIONAL RESEARCH;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; GLUTAMIC ACID; HUMANS; MICE; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER AGENTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80053221118     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002804     Document Type: Conference Paper

References (156)

1. D. D. Schoepp, Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 299, 12-20 (2001).
2. C. W. Cotman, D. T. Monaghan, A. H. Ganong, Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu. Rev. Neurosci. 11, 61-80 (1988).
3. D. C. Javitt, Glutamate as a therapeutic target in psychiatric disorders. Mol. Psychiatry 9, 984-997, 979 (2004).
4. R. Anwyl, Metabotropic glutamate receptors: Electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev. 29, 83-120 (1999).
5. S. Nakanishi, Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity. Neuron 13, 1031-1037 (1994).
6. C. Betancur, Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting. Brain Res. 1380, 42-77 (2011).
7. D. D. Krueger, M. F. Bear, Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411-429 (2011).
8. International Schizophrenia Consortium, S. M. Purcell, N. R. Wray, J. L. Stone, P. M. Visscher, M. C. O'Donovan, P. F. Sullivan, P. Sklar, Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
9. G. R. Uhl, T. Drgon, C. Johnson, C. Y. Li, C. Contoreggi, J. Hess, D. Naiman, Q. R. Liu, Molecular genetics of addiction and related heritable phenotypes: Genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects. Ann. N. Y. Acad. Sci. 1141, 318-381 (2008).
10. J. H. Miles, Autism spectrum disorders-A genetics review. Genet. Med. 13, 278-294 (2011).
11. E. D. Luby, J. S. Gottlieb, B. D. Cohen, G. Rosenbaum, E. F. Domino, Model psychoses and schizophrenia. Am. J. Psychiatry 119, 61-67 (1962).
12. J. H. Krystal, L. P. Karper, J. P. Seibyl, G. K. Freeman, R. Delaney, J. D. Bremner, G. R. Heninger, M. B. Bowers Jr., D. S. Charney, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214 (1994).
13. D. C. Javitt, S. R. Zukin, Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308 (1991).
14. J. T. Coyle, The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 3, 241-253 (1996).
15. D. C. Javitt, Glutamate and schizophrenia: Phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78, 69-108 (2007).
16. L. V. Kristiansen, I. Huerta, M. Beneyto, J. H. Meador-Woodruff, NMDA receptors and schizophrenia. Curr. Opin. Pharmacol. 7, 48-55 (2007).
17. P. J. Harrison, D. R. Weinberger, Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol. Psychiatry 10, 40-68 (2005).
18. S. J. Tsai, Central N-acetyl aspartylglutamate deficit: A possible pathogenesis of schizophrenia. Med. Sci. Monit. 11, HY39-HY45 (2005).
19. I. Wonodi, R. Schwarcz, Cortical kynurenine pathway metabolism: A novel target for cognitive enhancement in schizophrenia. Schizophr. Bull. 36, 211-218 (2010).
20. K. R. Linderholm, E. Skogh, S. K. Olsson, M. L. Dahl, M. Holtze, G. Engberg, M. Samuelsson, S. Erhardt, Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 10.1093/schbul/sbq086 (2010).
21. I. Bendikov, C. Nadri, S. Amar, R. Panizzutti, J. De Miranda, H. Wolosker, G. Agam, A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr. Res. 90, 41-51 (2007).
22. K. Hashimoto, G. Engberg, E. Shimizu, C. Nordin, L. H. Lindström, M. Iyo, Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 767-769 (2005).
23. C. Madeira, M. E. Freitas, C. Vargas-Lopes, H. Wolosker, R. Panizzutti, Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr. Res. 101, 76-83 (2008).
24. L. Verrall, P. W. Burnet, J. F. Betts, P. J. Harrison, The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Mol. Psychiatry 15, 122-137 (2010).
25. V. Labrie, R. Fukumura, A. Rastogi, L. J. Fick, W. Wang, P. C. Boutros, J. L. Kennedy, M. O. Semeralul, F. H. Lee, G. B. Baker, D. D. Belsham, S. W. Barger, Y. Gondo, A. H. Wong, J. C. Roder, Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum. Mol. Genet. 18, 3227-3243 (2009).
26. A. C. Basu, G. E. Tsai, C. L. Ma, J. T. Ehmsen, A. K. Mustafa, L. Han, Z. I. Jiang, M. A. Benneyworth, M. P. Froimowitz, N. Lange, S. H. Snyder, R. Bergeron, J. T. Coyle, Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol. Psychiatry 14, 719-727 (2009).
27. L. M. DeVito, D. T. Balu, B. R. Kanter, C. Lykken, A. C. Basu, J. T. Coyle, H. Eichenbaum, Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology. Genes Brain Behav. 10, 210-222 (2011).
28. V. Labrie, W. Wang, S. W. Barger, G. B. Baker, J. C. Roder, Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice. Genes Brain Behav. 9, 11-25 (2010).
29. K. Q. Do, J. H. Cabungcal, A. Frank, P. Steullet, M. Cuenod, Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 19, 220-230 (2009).
30. M. S. Kayser, J. Dalmau, The emerging link between autoimmune disorders and neuropsychiatric disease. J. Neuropsychiatry Clin. Neurosci. 23, 90-97 (2011).
31. Office of National Drug Control Policy, The Economic Costs of Drug Abuse in the United States, 1992-2002 (Executive Office of the President, Office of National Drug Control Policy, Washington, DC, 2004); http://www.ncjrs.gov/ ondcppubs/publications/pdf/economic-costs.pdf
32. P. W. Kalivas, The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10, 561-572 (2009).
33. P. W. Kalivas, N. D. Volkow, The neural basis of addiction: A pathology of motivation and choice. Am. J. Psychiatry 162, 1403-1413 (2005).
34. R. Z. Goldstein, N. D. Volkow, Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159, 1642-1652 (2002).
35. L. J. vanderschuren, B. J. Everitt, Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 305, 1017-1019 (2004).
36. F. Kasanetz, V. Deroche-Gamonet, N. Berson, E. Balado, M. Lafourcade, O. Manzoni, P. V. Piazza, Transition to addiction is associated with a persistent impairment in synaptic plasticity. Science 328, 1709-1712 (2010).
37. M. Martin, B. T. Chen, F. W. Hopf, M. S. Bowers, A. Bonci, Cocaine self-administration selectively abolishes LTD in the core of the nucleus accumbens. Nat. Neurosci. 9, 868-869 (2006).
38. K. Moussawi, A. Pacchioni, M. Moran, M. F. Olive, J. T. Gass, A. Lavin, P. W. Kalivas, N-acetylcysteine reverses cocaine-induced metaplasticity. Nat. Neurosci. 12, 182-189 (2009).
39. L. A. Knackstedt, S. LaRowe, P. Mardikian, R. Malcolm, H. Upadhyaya, S. Hedden, A. Markou, P. W. Kalivas, The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol. Psychiatry 65, 841-845 (2009).
40. A. Madayag, K. S. Kau, D. Lobner, J. R. Mantsch, S. Wisniewski, D. A. Baker, Drug-induced plasticity contributing to heightened relapse susceptibility: Neurochemical changes and augmented reinstatement in high-intake rats. J. Neurosci. 30, 210-217 (2010).
41. W. Zhou, P. W. Kalivas, N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol. Psychiatry 63, 338-340 (2008).
42. Y. Sari, K. D. Smith, P. K. Ali, G. V. Rebec, Upregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats. J. Neurosci. 29, 9239-9243 (2009).
43. L. A. Knackstedt, R. I. Melendez, P. W. Kalivas, Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biol. Psychiatry 67, 81-84 (2010).
44. K. M. Myers, W. A. Carlezon Jr., M. Davis, Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 36, 274-293 (2011).
45. R. J. Kelleher III, M. F. Bear, The autistic neuron: Troubled translation? Cell 135, 401-406 (2008).
46. A. L. Nordström, L. Farde, F. A. Wiesel, K. Forslund, S. Pauli, C. Halldin, G. Uppfeldt, Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol. Psychiatry 33, 227-235 (1993).
47. S. Kapur, R. Zipursky, C. Jones, G. Remington, S. Houle, Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157, 514-520 (2000).
48. O. D. Howes, A. Egerton, V. Allan, P. McGuire, P. Stokes, S. Kapur, Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Curr. Pharm. Des. 15, 2550-2559 (2009).
49. P. S. Talbot, S. Bradley, C. P. Clarke, K. O. Babalola, A. W. Philipp, G. Brown, A. W. McMahon, J. C. Matthews, Brain serotonin transporter occupancy by oral sibutramine dosed to steady state: A PET study using 11C-DASB in healthy humans. Neuropsychopharmacology 35, 741-751 (2010).
50. R. M. Moresco, M. Matarrese, F. Fazio, PET and SPET molecular imaging: Focus on serotonin system. Curr. Top. Med. Chem. 6, 2027-2034 (2006).
51. C. Burger, A. Deschwanden, S. Ametamey, A. Johayem, B. Mancosu, M. Wyss, G. Hasler, A. Buck, Evaluation of a bolus/infusion protocol for 11C-ABP688, a PET tracer for mGluR5. Nucl. Med. Biol. 37, 845-851 (2010).
52. J. Passchier, G. Gentile, R. Porter, H. Herdon, C. Salinas, S. Jakobsen, H. Audrain, M. Laruelle, R. N. Gunn, Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse 64, 542-549 (2010).
53. D. Umbricht, M. Martin-Facklam, E. Pizzagalli, E. Youssef, K. Yoo, E. Doerflinger, A. Bausch, R. Arrowsmith, D. Alberati, L. Santarelli, Glycine transporter type 1 (GLYT1) inhibition RG1678: Results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schiz. Bull. 37 (Suppl. 1), 324 (2011).
54. D. Alberati, E. Borroni, J. Moreau, D. Hainzl, E. Pinnard, J. G. Wettstein, Partial occupancy of the glycine transporter type 1 in rat by RG1678 leads to efficacy in mouse models relevant to schizophrenia. Schiz. Bull. 37 (Suppl. 1), 286 (2011).
55. E. Borroni, D. F. Wong, T. L. Wallace, Y. Zhou, A. Kumar, E. Pinard, D. Alberati, Partial occupancy of the glycine transporter type 1 in monkey by RG1678 leads to efficacy in a model of prefrontal cortical function. Schiz. Bull. 37 (Suppl. 1), 296-297 (2011).
56. R. Näätänen, The mismatch negativity: A powerful tool for cognitive neuroscience. Ear Hear. 16, 6-18 (1995).
57. D. C. Javitt, Intracortical mechanisms of mismatch negativity dysfunction in schizophrenia. Audiol. Neurootol. 5, 207-215 (2000).
58. D. C. Javitt, A. M. Shelley, G. Silipo, J. A. Lieberman, Deficits in auditory and visual contextdependent processing in schizophrenia: Defining the pattern. Arch. Gen. Psychiatry 57, 1131-1137 (2000).
59. D. Umbricht, S. Krljes, Mismatch negativity in schizophrenia: A meta-analysis. Schizophr. Res. 76, 1-23 (2005).
60. G. A. Light, D. L. Braff, Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 62, 127-136 (2005).
61. D. Umbricht, R. Koller, L. Schmid, A. Skrabo, C. Grübel, T. Huber, H. Stassen, How specific are deficits in mismatch negativity generation to schizophrenia? Biol. Psychiatry 53, 1120-1131 (2003).
62. M. Gomot, R. Blanc, H. Clery, S. Roux, C. Barthelemy, N. Bruneau, Candidate electrophysiological endophenotypes of hyper-reactivity to change in autism. J. Autism Dev. Disord. 41, 705-714 (2011).
63. M. A. Dunn, H. Gomes, J. Gravel, Mismatch negativity in children with autism and typical development. J. Autism Dev. Disord. 38, 52-71 (2008).
64. E. Pekkonen, Mismatch negativity in aging and in Alzheimer's and Parkinson's diseases. Audiol. Neurootol. 5, 216-224 (2000).
65. D. C. Javitt, M. Steinschneider, C. E. Schroeder, J. C. Arezzo, Role of cortical N-methyl- D-aspartate receptors in auditory sensory memory and mismatch negativity generation: Implications for schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 93, 11962-11967 (1996).
66. B. Oranje, B. N. van Berckel, C. Kemner, J. M. van Ree, R. S. Kahn, M. N. Verbaten, The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 22, 293-302 (2000).
67. K. Heekeren, J. Daumann, A. Neukirch, C. Stock, W. Kawohl, C. Norra, T. D. Waberski, E. Gouzoulis-Mayfrank, Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology 199, 77-88 (2008).
68. I. Kreitschmann-Andermahr, T. Rosburg, U. Demme, E. Gaser, H. Nowak, H. Sauer, Effect of ketamine on the neuromagnetic mismatch field in healthy humans. Brain Res. Cogn. Brain Res. 12, 109-116 (2001).
69. D. Umbricht, L. Schmid, R. Koller, F. X. Vollenweider, D. Hell, D. C. Javitt, Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 57, 1139-1147 (2000).
70. R. S. Ehrlichman, C. R. Maxwell, S. Majumdar, S. J. Siegel, Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J. Cogn. Neurosci. 20, 1403-1414 (2008).
71. D. Tikhonravov, T. Neuvonen, A. Pertovaara, K. Savioja, T. Ruusuvirta, R. Näätänen, S. Carlson, Effects of an NMDA-receptor antagonist MK-801 on an MMN-like response recorded in anesthetized rats. Brain Res. 1203, 97-102 (2008).
72. D. Umbricht, D. Vyssotki, A. Latanov, R. Nitsch, H. Lipp, Deviance-related electrophysiological activity in mice: Is there mismatch negativity in mice? Clin. Neurophysiol. 116, 353-363 (2005).
73. D. C. Javitt, M. Jayachandra, R. W. Lindsley, C. M. Specht, C. E. Schroeder, Schizophrenialike deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin. Neurophysiol. 111, 833-836 (2000).
74. C. R. Maxwell, R. S. Ehrlichman, Y. Liang, D. Trief, S. J. Kanes, J. Karp, S. J. Siegel, Ketamine produces lasting disruptions in encoding of sensory stimuli. J. Pharmacol. Exp. Ther. 316, 315-324 (2006).
75. D. Umbricht, D. Vyssotky, A. Latanov, R. Nitsch, R. Brambilla, P. D'Adamo, H. P. Lipp, Midlatency auditory event-related potentials in mice: Comparison to midlatency auditory ERPs in humans. Brain Res. 1019, 189-200 (2004).
76. M. J. Gandal, J. C. Edgar, R. S. Ehrlichman, M. Mehta, T. P. Roberts, S. J. Siegel, Validating g oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry 68, 1100-1106 (2010).
77. B. F. O'Donnell, J. L. Vohs, W. P. Hetrick, C. A. Carroll, A. Shekhar, Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int. J. Psychophysiol. 53, 45-55 (2004).
78. T. W. Wilson, D. C. Rojas, M. L. Reite, P. D. Teale, S. J. Rogers, Children and adolescents with autism exhibit reduced MEG steady-state g responses. Biol. Psychiatry 62, 192-197 (2007).
79. G. Gonzalez-Burgos, D. A. Lewis, GABA neurons and the mechanisms of network oscillations: Implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull. 34, 944-961 (2008).
80. D. Tomasi, N. D. Volkow, Functional connectivity density mapping. Proc. Natl. Acad. Sci. U.S.A. 107, 9885-9890 (2010).
81. D. I. Horn, C. Yu, J. Steiner, J. Buchmann, J. Kaufmann, A. Osoba, U. Eckert, K. C. Zierhut, K. Schiltz, H. He, B. Biswal, B. Bogerts, M. Walter, Glutamatergic and resting-state functional connectivity correlates of severity in major depression-The role of pregenual anterior cingulate cortex and anterior insula. Front. Syst. Neurosci. 4, 33 (2010).
82. H. Y. Zhang, S. J. Wang, B. Liu, Z. L. Ma, M. Yang, Z. J. Zhang, G. J. Teng, Resting brain connectivity: Changes during the progress of Alzheimer disease. Radiology 256, 598-606 (2010).
83. Y. I. Sheline, M. E. Raichle, A. Z. Snyder, J. C. Morris, D. Head, S. Wang, M. A. Mintun, Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 67, 584-587 (2010).
84. M. J. Hoptman, X. N. Zuo, P. D. Butler, D. C. Javitt, D. D'Angelo, C. J. Mauro, M. P. Milham, Amplitude of low-frequency oscillations in schizophrenia: A resting state fMRI study. Schizophr. Res. 117, 13-20 (2010).
85. C. Kelly, X. N. Zuo, K. Gotimer, C. L. Cox, L. Lynch, D. Brock, D. Imperati, H. Garavan, J. Rotrosen, F. X. Castellanos, M. P. Milham, Reduced interhemispheric resting state functional connectivity in cocaine addiction. Biol. Psychiatry 69, 684-692 (2011).
86. M. Magnuson, W. Majeed, S. D. Keilholz, Functional connectivity in blood oxygenation level-dependent and cerebral blood volume-weighted resting state functional magnetic resonance imaging in the rat brain. J. Magn. Reson. Imaging 32, 584-592 (2010).
87. K. O. Lim, J. A. Helpern, Neuropsychiatric applications of DTI-A review. NMR Biomed. 15, 587-593 (2002).
88. K. H. Karlsgodt, T. A. Niendam, C. E. Bearden, T. D. Cannon, White matter integrity and prediction of social and role functioning in subjects at ultra-high risk for psychosis. Biol. Psychiatry 66, 562-569 (2009).
89. M. Ingalhalikar, D. Parker, L. Bloy, T. P. Roberts, R. Verma, Diffusion based abnormality markers of pathology: Toward learned diagnostic prediction of ASD. Neuroimage 57, 918-927 (2011).
90. D. N. Guilfoyle, S. Gerum, J. Hrabe, Murine diffusion imaging using snapshot interleaved EPI acquisition at 7T. J. Neurosci. Methods 199, 10-14 (2011).
91. J. M. Stone, Imaging the glutamate system in humans: Relevance to drug discovery for schizophrenia. Curr. Pharm. Des. 15, 2594-2602 (2009).
92. M. E. Henry, T. L. Lauriat, M. Shanahan, P. F. Renshaw, J. E. Jensen, Accuracy and stability of measuring GABA, glutamate, and glutamine by proton magnetic resonance spectroscopy: A phantom study at 4 Tesla. J. Magn. Reson. 208, 210-218 (2011).
93. J. R. Bustillo, L. M. Rowland, P. Mullins, R. Jung, H. Chen, C. Qualls, R. Hammond, W. M. Brooks, J. Lauriello, 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol. Psychiatry 15, 629-636 (2010).
94. K. Hashimoto, G. Engberg, E. Shimizu, C. Nordin, L. H. Lindström, M. Iyo, Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients. BMC Psychiatry 5, 6 (2005).
95. E. Toth, A. Lajtha, Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem. Res. 11, 393-400 (1986).
96. R. Waziri, Glycine therapy of schizophrenia. Biol. Psychiatry 23, 210-211 (1988).
97. J. T. Kantrowitz, D. C. Javitt, N-methyl-D-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? Brain Res. Bull. 83, 108-121 (2010).
98. G. E. Tsai, P. Y. Lin, Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr. Pharm. Des. 16, 522-537 (2010).
99. D. C. Javitt, Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr. Opin. Drug Discov. Devel. 12, 468-478 (2009).
100. D. C. Javitt, M. Frusciante, Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacology 129, 96-98 (1997).
101. D. C. Javitt, A. Balla, H. Sershen, A. Lajtha, A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol. Psychiatry 45, 668-679 (1999).
102. R. Bergeron, T. M. Meyer, J. T. Coyle, R. W. Greene, Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U.S.A. 95, 15730-15734 (1998).
103. D. Umbricht, K. Yoo, E. Youssef, E. Dorflinger, M. Martin-Facklam, A. Bausch, R. Arrowsmith, D. Alberati, S. R. Marder, L. Santarelli, Glycine transporter type 1 (GLYT1) inhibitor RG1678: Positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 35, S320-S321 (2010).
104. K. Hashimoto, Y. Fujita, M. Horio, S. Kunitachi, M. Iyo, D. Ferraris, T. Tsukamoto, Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 65, 1103-1106 (2009).
105. C. J. Swanson, M. Bures, M. P. Johnson, A. M. Linden, J. A. Monn, D. D. Schoepp, Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4, 131-144 (2005).
106. A. M. Linden, D. D. Schoepp, Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discov. Today Ther. Strateg. 3, 507-517 (2006).
107. G. Battaglia, J. A. Monn, D. D. Schoepp, In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 229, 161-164 (1997).
108. A. M. Linden, H. Shannon, M. Baez, J. L. Yu, A. Koester, D. D. Schoepp, Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology 179, 284-291 (2005).
109. E. Dunayevich, J. Erickson, L. Levine, R. Landbloom, D. D. Schoepp, G. D. Tollefson, Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33, 1603-1610 (2008).
110. M. P. Johnson, D. Barda, T. C. Britton, R. Emkey, W. J. Hornback, G. E. Jagdmann, D. L. McKinzie, E. S. Nisenbaum, J. P. Tizzano, D. D. Schoepp, Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 179, 271-283 (2005).
111. B. Moghaddam, B. W. Adams, Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352 (1998).
112. J. H. Krystal, A. Belger, D. C. D'Souza, A. Anand, D. S. Charney, G. K. Aghajanian, B. Moghaddam, Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 21, S143-S157 (1999).
113. D. D. Schoepp, R. A. Wright, L. R. Levine, B. Gaydos, W. Z. Potter, LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 6, 189-197 (2003).
114. J. Cartmell, J. A. Monn, D. D. Schoepp, The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161-170 (1999).
115. S. T. Patil, L. Zhang, F. Martenyi, S. L. Lowe, K. A. Jackson, B. V. Andreev, A. S. Avedisova, L. M. Bardenstein, I. Y. Gurovich, M. A. Morozova, S. N. Mosolov, N. G. Neznanov, A. M. Reznik, A. B. Smulevich, V. A. Tochilov, B. G. Johnson, J. A. Monn, D. D. Schoepp, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat. Med. 13, 1102-1107 (2007).
116. J. Cartmell, C. R. Salhoff, K. W. Perry, J. A. Monn, D. D. Schoepp, Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Res. 887, 378-384 (2000).
117. C. J. Swanson, D. D. Schoepp, A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann. N. Y. Acad. Sci. 1003, 309-317 (2003).
118. G. J. Marek, R. A. Wright, D. D. Schoepp, 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: Interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci. Lett. 403, 256-260 (2006).
119. J. Cartmell, D. D. Schoepp, Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75, 889-907 (2000).
120. D. D. Schoepp, G. J. Marek, Preclinical pharmacology of mGlu2/3 receptor agonists: Novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord. 1, 215-225 (2002).
121. J. H. Krystal, W. Abi-Saab, E. Perry, D. C. D'Souza, N. Liu, R. Gueorguieva, L. McDougall, T. Hunsberger, A. Belger, L. Levine, A. Breier, Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179, 303-309 (2005).
122. P. J. Conn, C. Tamminga, D. D. Schoepp, C. Lindsey, Schizophrenia: Moving beyond monoamine antagonists. Mol. Interv. 8, 99-107 (2008).
123. P. Skolnick, P. Popik, R. Trullas, Glutamate-based antidepressants: 20 years on. Trends Pharmacol. Sci. 30, 563-569 (2009).
124. G. Sanacora, C. A. Zarate, J. H. Krystal, H. K. Manji, Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426-437 (2008).
125. R. Machado-Vieira, G. Salvadore, L. A. Ibrahim, N. Diaz-Granados, C. A. Zarate Jr., Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr. Pharm. Des. 15, 1595-1611 (2009).
126. C. A. Zarate, J. Quiroz, J. Payne, H. K. Manji, Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol. Bull. 36, 35-83 (2002).
127. L. Aguado, A. San Antonio, L. Pérez, R. Del Valle, J. Gómez, Effects of the NMDA receptor antagonist ketamine on flavor memory: Conditioned aversion, latent inhibition, and habituation of neophobia. Behav. Neural Biol. 61, 271-281 (1994).
128. L. S. Garcia, C. M. Comim, S. S. Valvassori, G. Z. Réus, L. M. Barbosa, A. C. Andreazza, L. Stertz, G. R. Fries, E. C. Gavioli, F. Kapczinski, J. Quevedo, Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 140-144 (2008).
129. S. Maeng, C. A. Zarate Jr., J. Du, R. J. Schloesser, J. McCammon, G. Chen, H. K. Manji, Cellular mechanisms underlying the antidepressant effects of ketamine: Role of a-amino- 3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352 (2008).
130. G. A. Mickley, M. A. Schaldach, K. J. Snyder, S. A. Balogh, T. Len, K. Neimanis, P. Goulis, J. Hug, K. Sauchak, D. R. Remmers-Roeber, C. Walker, B. K. Yamamoto, Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats. Physiol. Behav. 64, 381-390 (1998).
131. J. S. Silvestre, R. Nadal, M. Pallarés, N. Ferré, Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress. Anxiety 5, 29-33 (1997).
132. D. Meloni, C. Gambarana, M. G. De Montis, P. Dal Prá, I. Taddei, A. Tagliamonte, Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol. Biochem. Behav. 46, 423-426 (1993).
133. C. M. Padovan, F. S. Guimarães, Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol. Biochem. Behav. 77, 15-19 (2004).
134. M. Papp, E. Moryl, New evidence for the antidepressant activity of MK-801, a noncompetitive antagonist of NMDA receptors. Pol. J. Pharmacol. 45, 549-553 (1993).
135. P. Skolnick, R. Miller, A. Young, K. Boje, R. Trullas, Chronic treatment with 1- aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology 107, 489-496 (1992).
136. R. Trullas, P. Skolnick, Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1-10 (1990).
137. R. M. Berman, A. Cappiello, A. Anand, D. A. Oren, G. R. Heninger, D. S. Charney, J. H. Krystal, Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354 (2000).
138. C. A. Zarate Jr., J. B. Singh, P. J. Carlson, N. E. Brutsche, R. Ameli, D. A. Luckenbaugh, D. S. Charney, H. K. Manji, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864 (2006).
139. M. H. Trivedi, A. J. Rush, S. R. Wisniewski, A. A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R. H. Howland, B. Lebowitz, P. J. McGrath, K. Shores-Wilson, M. M. Biggs, G. K. Balasubramani, M. Fava; STAR*D Study Team, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
140. N. Diazgranados, L. Ibrahim, N. E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W. A. Kammerer, Z. Quezado, D. A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H. K. Manji, C. A. Zarate Jr., A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793-802 (2010).
141. M. aan het Rot, K. A. Collins, J. W. Murrough, A. M. Perez, D. L. Reich, D. S. Charney, S. J. Matthew, Safety and efficacy of repeated-dose intravenous ketamine for treatmentresistant depression. Biol. Psychiatry 67, 139-145 (2010).
142. L. E. Phelps, N. Brutsche, J. R. Moral, D. A. Luckenbaugh, H. K. Manji, C. A. Zarate Jr., Family history of alcohol dependence and initial antidepressant response to an N-methyl-Daspartate antagonist. Biol. Psychiatry 65, 181-184 (2009).
143. R. B. Price, M. K. Nock, D. Charney, S. J. Mathew, Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522-526 (2009).
144. S. H. Preskorn, B. Baker, S. Kolluri, F. S. Menniti, M. Krams, J. W. Landen, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 28, 631-637 (2008).
145. G. Salvadore, B. R. Cornwell, V. Colon-Rosario, R. Coppola, C. Grillon, C. A. Zarate Jr., H. K. Manji, Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 65, 289-295 (2009).
146. G. Salvadore, B. R. Cornwell, F. Sambataro, D. Latov, V. Colon-Rosario, F. Carver, T. Holroyd, N. DiazGranados, R. Machado-Vieira, C. Grillon, W. C. Drevets, C. A. Zarate Jr., Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35, 1415-1422 (2010).
147. N. Li, B. Lee, R. J. Liu, M. Banasr, J. M. Dwyer, M. Iwata, X. Y. Li, G. Aghajanian, R. S. Duman, mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
148. L. W. Wang, E. Berry-Kravis, R. J. Hagerman, Fragile X: Leading the way for targeted treatments in autism. Neurotherapeutics 7, 264-274 (2010).
149. C. A. Erickson, J. E. Mullett, C. J. McDougle, Brief report: Acamprosate in fragile X syndrome. J. Autism Dev. Disord. 40, 1412-1416 (2010).
150. S. Jacquemont, A. Curie, V. Des Portes, M. G. Torrioli, E. Berry-Kravis, R. J. Hagerman, F. J. Ramos, K. Cornish, Y. He, C. Paulding, G. Neri, F. Chen, N. Hadjikhani, D. Martinet, J. Meyer, J. S. Beckmann, K. Delange, A. Brun, G. Bussy, F. Gasparini, T. Hilse, A. Floesser, J. Branson, G. Bilbe, D. Johns, B. Gomez-Mancilla, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to themGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra1 (2011).
151. P. Gazerani, X. Dong, M. Wang, U. Kumar, B. E. Cairns, Sensitization of rat facial cutaneous mechanoreceptors by activation of peripheral N-methyl-D-aspartate receptors. Brain Res. 1319, 70-82 (2010).
152. E. E. Castrillon, B. E. Cairns, M. Ernberg, K. Wang, B. J. Sessle, L. Arendt-Nielsen, P. Svensson, Effect of peripheral NMDA receptor blockade with ketamine on chronic myofascial pain in temporomandibular disorder patients: A randomized, double-blinded, placebo-controlled trial. J. Orofac. Pain 22, 122-130 (2008).
153. T. Walsh, J. M. McClellan, S. E. McCarthy, A. M. Addington, S. B. Pierce, G. M. Cooper, A. S. Nord, M. Kusenda, D. Malhotra, A. Bhandari, S. M. Stray, C. F. Rippey, P. Roccanova, V. Makarov, B. Lakshmi, R. L. Findling, L. Sikich, T. Stromberg, B. Merriman, N. Gogtay, P. Butler, K. Eckstrand, L. Noory, P. Gochman, R. Long, Z. Chen, S. Davis, C. Baker, E. E. Eichler, P. S. Meltzer, S. F. Nelson, A. B. Singleton, M. K. Lee, J. L. Rapoport, M. C. King, J. Sebat, Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539-543 (2008).
154. N. C. Allen, S. Bagade, M. B. McQueen, J. P. Ioannidis, F. K. Kavvoura, M. J. Khoury, R. E. Tanzi, L. Bertram, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat. Genet. 40, 827-834 (2008).
155. R. A. Sweet, R. A. Henteleff, W. Zhang, A. R. Sampson, D. A. Lewis, Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology 34, 374-389 (2009).
156. Funding: Manuscript preparation funded in part by grants R37MH49334, R01DA03383, and P50MH086385 to D.C.J. Supported by the Intramural Research Program at the National Institute of Mental Health. M.F.B. acknowledges support from NIH, Howard Hughes Medical Institute, FRAXA, and Simons Foundation Autism Research Initiative. Competing interests: D.C.J. holds intellectual property rights for use of NMDA modulators in treatment of mental disorders including schizophrenia and depression. He holds equity interest in Glytech Inc. He has served as a paid consultant to Schering-Plough, Takeda, NPS, Solvay, Sepracor, AstraZeneca, Pfizer, Cypress, Merck, Sunovion Eli Lilly, and BMS. He has received research grants from Pfizer, Roche, and Jazz and serves on the advisory board for Glytech and Promentis Pharmaceuticals. P.W.K. is listed as co-inventor on a patent application for the combined use of mGluR5-negative allosteric modulators and N-acetylcysteine in the treatment of addiction. P.W.K. has financial interest in Promentis Pharmaceuticals Inc., which is developing compounds to modulate the cystine-glutamate exchanger for treating schizophrenia. C.Z. is listed as a co-inventor on a patent application for the use of ketamine in major depression. C.Z. has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government. M.F.B. holds equity in, and is a paid consultant for, Seaside Therapeutics Inc. W.Z.P. is a paid consultant to AgeneBio, Amgen, AstraZeneca, BMS, InVivo, Orasi, Pfizer, and Theravance. Hoffmann-La Roche holds the patents for the compound RG1678 referred to in the paper. The other authors declare that they have no competing interests.